natgillin/translations-raw huggingface dataset:
Signs in your brain include: headaches, feeling very hungry, feeling sick (nausea) or being sick (vomiting), feeling tired, sleepy, restless, sleeping problems, aggressive behaviour, difficulty concentrating, slow reactions, depression, feeling confused, difficulty speaking (sometimes total loss of speech), changes in your sight, trembling, being unable to move (paralysis), tingling in the hands or arms, feeling numb and tingling often around the mouth, feeling dizzy, loss of self-control, being unable to look after yourself, fits, passing out.
Med znaki nizkega krvnega sladkorja v možganih so: glavobol, huda lakota, slabost v želodcu (siljenje na bruhanje) ali bruhanje, občutek utrujenosti, zaspanost, nemir, težave s spanjem, agresivno vedenje, težave z zbranostjo, počasne reakcije, depresija, občutek zmedenosti, težko govorjenje (včasih popolna izguba govora), spremembe vida, tresenje, nezmožnost gibanja (paraliza), mravljinčenje v rokah ali nogah, omrtvičenost in mravljinčenje, pogosto okrog ust, omotičnost, izguba samonadzora, nezmožnost poskrbeti zase, napadi krčev, nezavest.
The MAH shall ensure that in each Member State where Toujeo 300 units/ml is marketed, all healthcare professionals (HCPs) who are expected to prescribe or dispense Toujeo 300 units/ml, as well as all patients or their carers who are expected to use Toujeo 300 units/ml, are provided with educational material to address the risk(s) of Medication error (switching between 100 units/ml and 300 units/ml without dose adjustment).
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da bodo v vseh državah članicah, kjer se zdravilo Toujeo 300 enot/ml trži, vsi zdravstveni delavci, za katere se pričakuje, da bodo predpisovali ali izdajali zdravilo Toujeo 300 enot/ml, ter vsi bolniki ali njihovi skrbniki, za katere se pričakuje, da bodo uporabljali zdravilo Toujeo 300 enot/ml, prejeli izobraževalno gradivo, ki bo obravnavalo tveganje za napake pri uporabi zdravila (prehod med zdravilom s 100 enot/ml in zdravilom s 300 enot/ml brez prilagoditve odmerka).
• Angiotensin converting enzyme (ACE) inhibitors - for heart problems or high blood pressure.
• Zaviralce angiotenzinske konvertaze (zaviralci ACE) - za težave s srcem ali visok krvni tlak.
• Throw the pen away and use a new one.
• Zavrzite ta injekcijski peresnik in uporabite novega.
• Do not press at an angle - your thumb could block the dose selector from turning.
• Ne pritiskajte pod kotom (od strani), kajti vaš palec lahko onemogoči vrtenje izbirnika odmerka.
• Fibrates - for lowering high levels of blood fats.
• Fibrate - za znižanje visoke koncentracija maščob v krvi.
• a new sterile needle (see STEP 2).
• nova, sterilna igla (glejte 2.
If the DoubleStar pen is damaged, has not been stored correctly, if you are not sure that it is working properly or you notice that your blood sugar control is unexpectedly getting worse:
Če je peresnik DoubleStar poškodovan, če ni bil pravilno shranjen, če niste prepričani, da deluje pravilno, ali če opazite, da se vam urejenost krvnega sladkorja nepričakovano poslabša:
• Your insulin pen does not work properly.
• Insulinski peresnik ne deluje pravilno.
Dose adjustment may also be required, for example, if the patient's weight or life-style changes, if there is a change in the timing of insulin dose or if other circumstances arise that increase susceptibility to hypo-or hyperglycaemia (see section 4.4).
Prilagoditev odmerka je lahko potrebna tudi, če se npr. spremeni bolnikova telesna masa, slog življenja ali čas uporabe insulina, ali se pojavijo kakšne druge okoliščine, ki povečajo nagnjenost k hipo- ali hiperglikemiji (glejte poglavje 4.4).
Patients with type 2 diabetes mellitus The recommended daily starting dose is 0.2 units/kg followed by individual dose adjustments.
Bolniki s sladkorno boleznijo tipa 2 Priporočeni začetni dnevni odmerek je 0,2 enoti/kg, nato je treba odmerek individualno prilagoditi.
Please refer to the prescribing information of the medicinal product to which the patient is switching.
Glejte navodilo za uporabo zdravila, na katero prehaja bolnik.
Safety and efficacy of Toujeo have been demonstrated in a study in children aged 6 to less than 18 years.
Varnost in učinkovitost zdravila Toujeo sta bili dokazani v študiji pri otrocih, starih od 6 do manj kot 18 let.
IGF-1 receptor binding: The affinity of insulin glargine for the human IGF-1 receptor is approximately 5 to 8-fold greater than that of human insulin (but approximately 70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1 receptor with slightly lower affinity compared to human insulin.
Vezava na receptorje za IGF-1: Afiniteta insulina glargin za človeški receptor IGF-1 je približno 5- do 8-krat večja kot afiniteta humanega insulina (vendar približno 70- do 80-krat manjša kot afiniteta IGF1), presnovka M1 in M2 pa se na receptor za IGF-1 vežeta z nekoliko manjšo afiniteto kot humani insulin.
If you are 65 years or older, talk to your doctor as you may need a lower dose.
Uporaba pri starejših bolnikih (65 let in več) Če ste stari 65 let ali več, se posvetujte z zdravnikom, ker boste morda potrebovali manjši odmerek.
Beta-blockers like other “Sympatholytic medicines” (such as clonidine, guanethidine, reserpine - for high blood pressure) may make it harder to recognise warning signs of your blood sugar being too low (hypoglycaemia).
Zaviralci beta lahko, tako kot druga simpatikolitična zdravila (npr. klonidin, gvanetidin, rezerpin - za visok krvni tlak), otežijo prepoznavanje opozorilnih znakov prenizkega krvnega sladkorja (hipoglikemije).
Based on the results from clinical studies, the safety profile of Toujeo in elderly patients and in patients with renal impairment was similar to that of the overall population (see section 5.1).
Rezultati kliničnih študij kažejo, da so varnostne značilnosti zdravila Toujeo pri starejših bolnikih in bolnikih z okvaro ledvic podobne kot v splošni populaciji (glejte poglavje 5.1).
• For all injections, if no insulin comes out, the needle may be blocked.
• Za vse injekcije, če iz konice še vedno ne priteče insulin, je igla morda zamašena.
*GIR: Glucose infusion rate: determined as amount of glucose infused to maintain constant plasma glucose levels (hourly mean values).
*HIG: hitrost infundiranja glukoze; določena kot količina infundirane glukoze, potrebna za vzdrževanje stalne koncentracije glukoze v plazmi (povprečne urne vrednosti).
o To reduce potential underdose, Toujeo DoubleStar is recommended for patients requiring at least 20 units per day.
o Za zmanjšanje možnosti premajhnega odmerjanja je injekcijski peresnik Toujeo DoubleStar priporočljiv za bolnike, ki potrebujejo vsaj 20 enot na dan.
In patients with type 2 diabetes mellitus, Toujeo can also be given together with other anti-hyperglycaemic medicinal products.
Pri bolnikih s sladkorno boleznijo tipa 2 je mogoče zdravilo Toujeo uporabljati tudi skupaj z drugimi antihiperglikemičnimi zdravili.
• You can see roughly how many units of insulin are left by looking at where the plunger is on the insulin scale.
• Koliko enot insulina je še preostalo, lahko približno ocenite tako, da pogledate, kje ob merilu insulina je bat.
Please, see also section 2.
Prosimo, glejte tudi poglavje 2.
• Monoamine oxidase inhibitors (MAOIs) - for depression.
• Zaviralce monoaminooksidaze (zaviralci MAO) - za depresijo.
• You are taking or have taken certain other medicines (see section 2, "Other medicines and
• jemljete ali ste jemali določena druga zdravila (glejte poglavje 2, "Druga zdravila in zdravilo
Always carry a spare pen and spare needles in case they get lost or stop working.
Vedno imejte pri sebi rezervni peresnik in rezervne igle za primer, da peresnik izgubite ali da neha delovati.
What Toujeo is and what it is used for
Kaj je zdravilo Toujeo in za kaj ga uporabljamo
• Keep your pen at room temperature, below 30°C.
• Peresnik shranjujte na sobni temperaturi do 30 °C.
Pregnancy There is no clinical experience with use of Toujeo in pregnant women.
Nosečnost Kliničnih izkušenj z uporabo zdravila Toujeo pri nosečnicah ni.
• Your low blood sugar comes on slowly.
• se vam krvni sladkor znižuje počasi,
Based on your lifestyle, your blood sugar tests and your previous insulin use, your doctor will tell you:
Zdravnik vam bo glede na vaš slog življenja, izvide, meritev krvnega sladkorja in prejšnjo uporabo insulina povedal:
Since Toujeo is a clear solution, it does not require resuspension before use.
Zdravilo Toujeo je bistra raztopina, zato pred uporabo ne potrebuje resuspendiranja.
Toujeo DoubleStar is made to deliver the number of insulin units that your doctor prescribed.
Peresnik Toujeo DoubleStar je izdelan, da odmeri število enot insulina, ki vam jih je predpisal zdravnik.
900 units per pen
900 enot na peresnik
b Confirmed hypoglycaemia: Any severe hypoglycaemia and/or hypoglycaemia confirmed by plasma glucose value ≤3.9 mmol/l.
b Potrjena hipoglikemija: katera koli huda hipoglikemija in/ali hipoglikemija, potrjena z vrednostjo glukoze v plazmi ≤
• The Toujeo SoloStar pen contains 450 units of Toujeo.
• Peresnik Toujeo SoloStar vsebuje 450 enot zdravila Toujeo.
Mean dose of insulin glargine 100 units/ml by study end was 0.42 U/kg.
Povprečni odmerek insulina glargin 100 enot/ml je bil ob koncu študije 0,42 E/kg.
The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with insulin glargine is principally based on exposure to M1. Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable their concentration was independent of the administered dose and formulation of insulin glargine.
Farmakokinetični in farmakodinamski izsledki kažejo, da učinek subkutano injiciranega insulina glargin temelji predvsem na izpostavljenosti presnovku M1. Insulin glargin in presnovek M2 pri veliki večini preiskovancev nista bila zaznavna; če sta bila zaznavna, pa njuna koncentracija ni bila odvisna od uporabljenega odmerka in oblike insulina glargin.
If you notice signs of your blood sugar being too low (hypoglycaemia), take action to increase your blood sugar level straight away (see the box at the end of this leaflet).
Če opazite znake prenizkega krvnega sladkorja (hipoglikemije), ukrepajte tako, da boste koncentracijo krvnega sladkorja takoj zvišali (glejte okvir na koncu tega navodila).
• Diazoxide - for high blood pressure.
• Diazoksid - za visok krvni tlak.
At baseline, participants had a median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9 to 6.4% in the insulin glargine 100 units/ml group, and 6.2% to 6.6% in the standard care group throughout the duration of follow-up.
Izhodiščno so imeli preiskovanci mediano vrednost HbA1c 6,4 %; mediana vrednost HbA1c med zdravljenjem je segala od 5,9 do 6,4 % v skupini z insulinom glargin 100 enot/ml in od 6,2 % do 6,6 % v skupini s standardno oskrbo med celotnim trajanjem spremljanja.
The dose-response analysis showed that following the initial titration phase, the body weight adjusted doses in pediatric patients are higher than in adult patients at steady state.
Analiza odmerka in odziva je pokazala, da je pri pediatričnih bolnikih na telesno maso prilagojeni odmerek po uvodni titracijski fazi v stanju dinamičnega ravnovesja večji kot pri odraslih.
The total therapeutic insulin concentration (insulin glargine and its metabolites) found in type 1 diabetic patients was markedly lower than what would be required for a half maximal occupation of the IGF-1 receptor and the subsequent activation of the mitogenic-proliferative pathway initiated by the IGF-1 receptor.
Celotna terapevtska koncentracija insulina (insulina glargin in njegovih presnovkov) je bila pri sladkornih bolnikih tipa 1 bistveno manjša od koncentracije, potrebne za polovično največjo zasedenost receptorjev za IGF-1 in posledično aktivacijo mitogeno-proliferacijske poti, ki jo sproža receptor za IGF-1.
IGlar: Insulin glargine 100 units/ml a mITT: Modified intention-to-treat b Treatment difference: Toujeo- insulin glargine 100 units/ml; [95% Confidence Interval] c Change from baseline to Month 6 (observed case) d Change from baseline to Last main 6-month on-treatment value
IGlar: Insulin glargin 100 enot/ml a mZNZ: modificirano z-namenom-zdravljenja b Razlika med zdravljenjema: Toujeo - insulin glargin 100 enot/ml; [95 % interval zaupanja] c Sprememba od izhodišča do 6 meseca (opazovani primeri) d Sprememba od izhodišča do zadnje glavne vrednosti med 6 meseci zdravljenja
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
Če urejenost glukoze ni zadostna ali obstaja nagnjenost k hiper- ali hipoglikemijam, je treba pred spreminjanjem odmerka preveriti bolnikovo upoštevanje predpisane sheme zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
Over the course of this 6-year study, 42% of the insulin glargine 100 units/ml group did not experience any hypoglycaemia.
Med to 6-letno študijo 42 % preiskovancev v skupini z insulinom glargin 100 enot/ml ni imelo nobene hipoglikemije.
B Turn the dose selector until the dose pointer lines up with your dose.
B Zavrtite izbirnik odmerka, dokler kazalnik odmerka ni uravnan z vašim odmerkom.
The prolonged effect of insulin glargine may delay recovery from hypoglycaemia.
Podaljšani učinek insulina glargin lahko upočasni okrevanje po hipoglikemiji.
• You can clean the outside of your pen by wiping it with a damp cloth.
• Zunanjost peresnika lahko očistite tako, da ga obrišete z vlažno krpo.
This medicine contains less than 1 mmol (23 mg) sodium per dose.
Pomembne informacije o nekaterih sestavinah zdravila Toujeo To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek.
Severe allergic reactions (rare, may affect up to 1 in 1,000 people).The signs may include rash and itching all over the body, swelling of skin or mouth, shortness of breath, feeling faint (a fall in blood pressure) with fast heart beat and sweating.
Hude alergijske reakcije (redke, pojavijo se lahko pri največ 1 od 1.000 oseb) - med znaki so lahko izpuščaj in srbenje po vsem telesu, oteklost kože ali ust, kratka sapa, omedlevica (padec krvnega tlaka) s hitrim bitjem srca in znojenjem.
• The active substance is insulin glargine.
• Učinkovina je insulin glargin.
Clinical study safety data are not available for children under 6 years.
Za otroke, mlajše od 6 let, podatkov o varnosti iz kliničnih študij ni.
Injection sites must be rotated within a given injection area from one injection to the next (see section 4.8).
Mesto injiciranja na posameznem predelu je treba od injekcije do injekcije krožno menjati (glejte poglavje 4.8).
If the pen is new, you must perform safety tests before you use the pen for the first time until you see insulin coming out of the needle tip.
Če je peresnik nov, morate varnostni preizkus opraviti, preden peresnik prvič uporabite, in sicer dokler ne vidite, da je iz konice igle prišel insulin.
26 weeks of treatment
d 6-mesečno obdobje zdravljenja
These include patients: - in whom glycaemic control is markedly improved, - in whom hypoglycaemia develops gradually, - who are elderly, - after transfer from animal insulin to human insulin, - in whom an autonomic neuropathy is present, - with a long history of diabetes, - suffering from a psychiatric illness, - receiving concurrent treatment with certain other medicinal products (see section 4.5).
Med takšne spadajo bolniki, ki: - se jim urejenost glikemije občutno izboljša, - se jim hipoglikemija razvije počasi, - so starejši, - so po prehodu z živalskih na humana insulinska zdravila, - imajo avtonomno nevropatijo, - so z dolgo anamnezo sladkorne bolezni, - imajo kakšno psihiatrično bolezen, - sočasno prejemajo določena druga zdravila (glejte poglavje 4.5).
If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before using Toujeo.
Če kaj od naštetega velja za vas (ali če ste negotovi), se posvetujte z zdravnikom, medicinsko sestro ali farmacevtom, preden uporabite zdravilo Toujeo.
Figure 1: Activity profile at steady state in patients with type 1 diabetes in a 36-hour euglycaemic clamp study
Slika 1: Profil aktivnost v stanju dinamičnega ravnovesja pri bolnikih s sladkorno boleznijo tipa 1 v 36-urni študiji evglikemične uklenjenosti.
If you do not perform the safety test before each injection, you may get too little insulin.
Če pred vsakim injiciranjem ne izvedete varnostnega preizkusa, se lahko zgodi, da injicirate premajhen odmerek insulina.
Toujeo must not be used in insulin infusion pumps.
Zdravila Toujeo se ne sme uporabljati v infuzijskih črpalkah za insulin.
• Skin and allergic reactions at the injection site: The signs may include reddening, unusually intense pain when injecting, itching, hives, swelling or inflammation.
• Kožne in alergijske reakcije na mestu injiciranja - med znaki so lahko pordelost, nenavadno močna bolečina med injiciranjem, srbenje, urtikarija, otekanje ali vnetje.
Insulin glargine 100 units/ml did not alter the relative risk for CV disease and CV mortality when compared to standard of care.
Insulin glargin 100 enot/ml v primerjavi s standardno oskrbo ni spremenil relativega tveganja za KV bolezen ali KV umrljivost.
Re-use of needles increases the risk of blocked needles which may cause underdosing or overdosing (see section 4.4 and 6.6).
Ponovna uporaba igel poveča tveganje za zamašitev, to pa lahko povzroči premajhno ali preveliko odmerjanja (glejte poglavji 4.4 in 6.6).
EU/1/00/133/033 1 pen (SoloStar) EU/1/00/133/034 3 pens (SoloStar) EU/1/00/133/035 5 pens (SoloStar) EU/1/00/133/036 10 pens (SoloStar) EU/1/00/133/037 1 pen (DoubleStar) EU/1/00/133/038 3 pens (DoubleStar) EU/1/00/133/041 10 pens (DoubleStar)
EU/1/00/133/033 1 injekcijski peresnik (SoloStar) EU/1/00/133/034 3 injekcijski peresniki (SoloStar) EU/1/00/133/035 5 injekcijskih peresnikov (SoloStar) EU/1/00/133/036 10 injekcijskih peresnikov (SoloStar) EU/1/00/133/037 1 injekcijski peresnik (DoubleStar) EU/1/00/133/038 3 injekcijski peresniki (DoubleStar) EU/1/00/133/041 10 injekcijskih peresnikov (DoubleStar)
If you use a new pen, perform a safety test (see STEP 3).
Če uporabite nov peresnik, izvedite varnostni preizkus (3.
In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper-or hypoglycaemia.
V redkih primerih je zaradi prisotnosti takšnih protiteles proti insulinu treba prilagoditi odmerek insulina, da bi odpravili nagnjenost k hiper- ali hipoglikemiji.
In type 1 diabetes mellitus, Toujeo must be combined with short-/rapid-acting insulin to cover mealtime insulin requirements.
Pri sladkorni bolezni tipa 1 je treba zdravilo Toujeo uporabljati v kombinaciji s kratko-/hitrodelujočim insulinom za kritje potreb po insulinu ob obrokih.
Instead, regular insulin administered intravenously is recommended in such cases.
V takšnih primerih je treba intravensko uporabiti običajni insulin.
To prevent the possible transmission of disease, insulin pens should never be used for more than one person, even when the needle is changed.
Da bi preprečili možen prenos bolezni, se insulinski peresniki nikoli ne smejo uporabljati pri več kot eni osebi, tudi če se zamenja injekcijska igla.
• You change the area of skin where you inject insulin.
• Zamenjate predel kože, kamor injicirate insulin, npr. s stegna na nadlaket.
The rates of severe hypoglycaemia (affected participants per 100 participant years of exposure) were 1.05 for insulin glargine 100 units/ml and 0.30 for standard care group and the rates of confirmed non-severe hypoglycaemia were 7.71 for insulin glargine 100 units/ml and 2.44 for standard care group.
Deleža hudih hipoglikemij (prizadeti preiskovanci na 100 preiskovanec-let izpostavljenosti) sta bila 1,05 za insulin glargin 100 enot/ml in 0,30 za standardno oskrbo, deleža potrjenih ne-hudih hipoglikemij pa sta bila 7,17 za insulin glargin in 7,71 za standardno oskrbo.
If you do, it could lead to very high blood sugar and a build-up of acid in the blood (ketoacidosis).
Če ga prenehate uporabljati, se vam lahko krvni sladkor zelo zviša in v krvi se lahko kopiči kislina (ketoacidoza).
Toujeo contains 3 times more insulin in 1 ml than standard insulin, which contains 100 unit/ml.
Zdravilo Toujeo vsebuje v 1 ml 3-krat več insulina kot standardni insulin: standardni insulin vsebuje 100 enot/ml.
The safety and efficacy of Toujeo in children below 6 years of age have not been established.
Varnost in učinkovitost zdravila Toujeo pri otrocih, mlajših od 6 let, nista bili ugotovljeni.
Effects of insulin glargine 100 units/ml (once daily) on diabetic retinopathy were evaluated in an open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2 diabetic patients in which progression of retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by fundus photography.
Učinke insulina glargin 100 enot/ml (enkrat na dan) na diabetično retinopatijo so raziskali v odprti, petletni, z NPH kontrolirani študiji (NPH uporabljan dvakrat na dan) pri 1.024 bolnikih s sladkorno boleznijo tipa 2; napredovanje retinopatije za 3 ali več stopenj po lestvici ETDRS (Early Treatment Diabetic Retinopathy Study) so v študiji preiskovali s slikanjem očesnega ozadja.
However, only very rarely, this will require a change to your insulin dose.
V redkih primerih to zahteva spremembo odmerka insulina.
To avoid dosing errors and potential overdose, the patients must be instructed to never use a syringe to remove Toujeo (insulin glargine 300 units/ml) from the Toujeo SoloStar pre-filled pen or Toujeo DoubleStar pre-filled pen (see section 4.9 and 6.6).
Za preprečitev napak pri odmerjanju in možnega prevelikega odmerjanja je treba bolnikom naročiti, naj nikdar z brizgo ne jemljejo zdravila Toujeo (insulin glargin 300 enot/ml) iz napolnjenega injekcijskega peresnika Toujeo SoloStar ali napolnjenega injekcijskega peresnika Toujeo DoubleStar (glejte poglavji 4.9 in 6.6).
• Your pen contains a total of 450 units of insulin.
• Vaš peresnik vsebuje vsega skupaj 450 enot insulina.
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to hypoglycaemia include anti-hyperglycaemic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics.
Med zdravili, ki lahko povečajo učinek znižanja glukoze v krvi in povečajo nagnjenost k hipoglikemiji, so antihiperglikemična zdravila, zaviralci angiotenzinske konvertaze (ACE), dizopiramid, fibrati, fluoksetin, zaviralci monoaminooksidaze (MAO), pentoksifilin, propoksifen, salicilati in sulfonamidni antibiotiki.
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure.
Opisani so bili primeri srčnega popuščanja med uporabo pioglitazona skupaj z insulinom, zlasti pri bolnikih z dejavniki tveganja za srčno popuščanje.
In a clinical pharmacology study, intravenous insulin glargine and human insulin have been shown to be equipotent when given at the same doses.
Klinična farmakološka študija je pokazala, da sta intravensko uporabljeni insulin glargin in humani insulin v enakih odmerkih ekvipotentna.
including in Toujeo therapy, are considerably lower than the pharmacological concentrations required to activate the IGF-1 pathway.
Vendar so terapevtske koncentracije med insulinskim zdravljenjem, vključno z zdravljenjem z zdravilom Toujeo, bistveno manjše kot farmakološke koncentracije, potrebne za aktivacijo poti IGF-1.
EU/1/00/133/039 6 pens (2 packs of 3) EU/1/00/133/040 9 pens (3 packs of 3)
EU/1/00/133/039 6 injekcijskih peresnikov (2 pakiranji po 3) EU/1/00/133/040 9 injekcijskih peresnikov (3 pakiranja po 3)